SPM Past Earnings Performance
Past criteria checks 2/6
SPM's earnings have been declining at an average annual rate of -22.3%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been declining at an average rate of 25.7% per year. SPM's return on equity is 2.4%, and it has net margins of 3.6%.
Key information
-22.3%
Earnings growth rate
-22.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | -25.7% |
| Return on equity | 2.4% |
| Net Margin | 3.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SPM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 529,844 | 18,980 | 35,247 | 0 |
| 31 Dec 22 | 699,633 | 24,623 | 40,544 | 0 |
| 30 Sep 22 | 713,055 | 24,429 | 43,998 | 0 |
| 31 Mar 22 | 677,877 | 23,113 | 44,714 | 0 |
| 31 Dec 21 | 709,890 | 20,183 | 46,297 | 0 |
| 30 Sep 21 | 689,117 | 15,742 | 51,304 | 0 |
| 30 Jun 21 | 705,330 | 13,861 | 51,966 | 0 |
| 31 Mar 21 | 675,657 | 8,048 | 62,938 | 0 |
| 31 Dec 20 | 609,994 | 8,187 | 69,011 | 0 |
| 30 Sep 20 | 552,712 | 8,180 | 70,464 | 0 |
| 31 Mar 20 | 487,346 | 9,224 | 71,671 | 0 |
| 31 Dec 19 | 492,476 | 9,086 | 70,330 | 0 |
| 30 Jun 18 | 380,020 | 11,855 | 75,829 | 0 |
| 31 Mar 18 | 411,015 | 10,542 | 77,610 | 0 |
| 31 Dec 17 | 636,023 | 15,741 | 67,806 | 0 |
| 30 Sep 17 | 668,412 | 360 | 68,461 | 0 |
| 30 Jun 17 | 673,648 | 247 | 62,894 | 0 |
| 31 Mar 17 | 649,328 | 7,787 | 58,237 | 0 |
| 31 Dec 16 | 460,756 | 7,886 | 58,015 | 0 |
| 30 Sep 14 | 523,879 | 30,404 | 51,605 | 0 |
| 30 Jun 14 | 480,270 | 27,360 | 49,639 | 0 |
| 31 Mar 14 | 471,065 | 19,377 | 51,447 | 0 |
| 31 Dec 13 | 441,131 | 17,504 | 48,678 | 0 |
Quality Earnings: SPM has high quality earnings.
Growing Profit Margin: SPM's current net profit margins (3.6%) are higher than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SPM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: SPM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SPM had negative earnings growth (-22.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).
Return on Equity
High ROE: SPM's Return on Equity (2.4%) is considered low.